Samil Pharmaceutical Co Ltd
KRX:000520
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Y
|
Yamadai Corp
TSE:7426
|
JP |
|
Goodpatch Inc
TSE:7351
|
JP |
|
METISA Metalurgica Timboense SA
BOVESPA:MTSA4
|
BR |
|
Inpex Corp
TSE:1605
|
JP |
|
Hims & Hers Health Inc
NYSE:HIMS
|
US |
|
N
|
Neuca SA
WSE:NEU
|
PL |
|
AdvanSix Inc
NYSE:ASIX
|
US |
Samil Pharmaceutical Co Ltd
Research & Development
Samil Pharmaceutical Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Samil Pharmaceutical Co Ltd
KRX:000520
|
Research & Development
-₩8.8B
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-20%
|
|
|
Yuhan Corp
KRX:000100
|
Research & Development
-₩198.2B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-18%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Research & Development
-₩169.7B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Research & Development
-₩195.8B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-2%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Research & Development
-₩8.7B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-9%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Research & Development
-₩5.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
Samil Pharmaceutical Co Ltd
Glance View
SAMIL PHARMACEUTICAL Co., Ltd. engages in the development and manufacture of pharmaceutical products. The company is headquartered in Seoul, Seoul. The Company’s products portfolio consists of gastro-intestinal drugs such as antiulcerants, gastroprokinetic agents, digestive enzymes with nutrients and laxatives under the brand names of Plybutine, Gliptide and others; antipyretic, analgesic and anti-inflammatory agents under the brand name Brufen; nutritional supplements such as vitamins, minerals and immunosuppressants, and others including antigout agents, anti-parkinsonism agents and others. In addition, it is engaged in the provision of miscellaneous goods. The firm distributes its products within domestic market and to overseas markets. On November 29, 2013, it transferred its entire shares of a Korea-based company, which is engaged in the sale of medical products.
See Also
What is Samil Pharmaceutical Co Ltd's Research & Development?
Research & Development
-8.8B
KRW
Based on the financial report for Sep 30, 2025, Samil Pharmaceutical Co Ltd's Research & Development amounts to -8.8B KRW.
What is Samil Pharmaceutical Co Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-20%
Over the last year, the Research & Development growth was -91%. The average annual Research & Development growth rates for Samil Pharmaceutical Co Ltd have been -52% over the past three years , -23% over the past five years , and -20% over the past ten years .
